Hematopoietic Progenitor Cells - Cord Blood
造血祖细胞 - 脐带血
基本信息
- 批准号:8056503
- 负责人:
- 金额:$ 31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1993
- 资助国家:美国
- 起止时间:1993-09-17 至 2015-01-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Umbilical cord blood (CB) is used increasingly to restore hematopoiesis in transplant patients lacking sibling, or unrelated donors. A major disadvantage of CB transplantation (CBT) is the low cell dose with resultant delays in neutrophil and platelet engraftment, as well as a high rate of engraftment failure. A major hypothesis of this grant is that ex vivo-expanded CB progenitors will provide more rapid hematopoietic reconstitution and less engraftment failure than unmanipulated CB. In the two clinical CB expansion trials conducted during the last RO1 funding period, CD133+ progenitors were isolated and cultured ex vivo in a liquid culture system targeting committed, or more primitive hematopoietic progenitors. In those sequential trials, trends in faster time to engraftment were seen, but significant losses of CD34+ progenitors occurred. To avoid the need for positive selection, which results in a substantial loss of CD34+ cells, we have developed an alternative approach that involves the ex vivo co-culture of CB mononuclear cells (MNC) with bone marrow-derived mesenchymal stem cells (MSC). We hypothesize that MSC, by functioning as a surrogate hematopoietic 'niche', will provide a more suitable microenvironment for the expansion of lineage-committed CB hematopoietic progenitors than afforded by current liquid suspension culture systems. As accrual to the current CB expansion trials nears completion, this competitive renewal application will focus on the clinical evaluation of CB expansion in MSC co-cultures, with the long-term goal of improving neutrophil and platelet engraftment in CBT patients. Although a low cell dose is clearly the chief limitation of CBT, a number of investigators have also reported a deficit in the homing of CB cells to the marrow. Thus, it is conceivable that even with optimal ex vivo expansion, inadequate homing may limit the rapidity of engraftment which is the goal of this proposal. The homing defect has been attributed to low levels of fucosylation of cell surface molecules responsible for binding to P- and/or E-selectins expressed by the marrow microvasculature. This interaction is a key component of the recruitment of hematopoietic progenitors to the marrow. We hypothesize that increasing the level of CB cell surface fucosylation will improve interactions with selectins, thereby improving homing and engraftment. Aim 3 will evaluate the modification of unmanipulated and expanded CB progenitor cells with a fucosyltransferase, as a means to facilitate their recruitment to the marrow.
PUBLIC HEALTH RELEVANCE: Umbilical cord blood is being used increasingly for many patients with high-risk hematological malignancies and genetic disorders who do not have a bone marrow donor, but is associated with a longer time to engraftment compared to marrow. The expansion of cord blood in the laboratory prior to infusion appears to shorten time to engraftment; additionally the treatment of the cord blood with a sugar molecule prior to infusion appears to improve its ability to home to the bone marrow quickly. Both these strategies will be explored in the grant thereby making the transplant safer for patients in terms of infectious and bleeding complications and will thus improve survival.
描述(由申请人提供):脐带血(CB)越来越多地用于恢复缺乏兄弟姐妹或无关供体的移植患者中的造血。 CB移植(CBT)的主要缺点是低细胞剂量,导致嗜中性粒细胞和血小板植入的延迟,以及高植入失败率。这项赠款的一个主要假设是,与无操纵的CB相比,过体扩展的CB祖细胞将提供更快的造血重建和植入失败。在最后一个RO1融资期间进行的两项临床CB扩张试验中,在靶向承诺或更原始的造血祖细胞的液体培养系统中分离了CD133+祖细胞,并在体内进行了培养。在那些顺序的试验中,看到了更快的植入时间的趋势,但CD34+祖细胞的显着损失发生了明显的损失。为了避免需要阳性选择,这会导致CD34+细胞的大量损失,我们开发了一种涉及CB单核细胞(MNC)与骨髓衍生的间充质干细胞(MSC)的离体共文化(MNC)。我们假设MSC通过充当替代造型造血的“利基”,将提供比当前液体悬浮培养系统所提供的谱系CB造血祖细胞的扩展更合适的微环境。由于当前的CB扩展试验即将完成,因此该竞争性更新应用将集中在MSC共培养中CB扩张的临床评估上,其长期目标是改善CBT患者中性粒细胞和血小板植入。尽管低细胞剂量显然是CBT的主要局限性,但许多研究者还报告了CB细胞向骨髓寄养的不足。因此,可以想象的是,即使有最佳的离体扩张,归巢不足也可能限制植入的速度,这是该提议的目标。归因缺陷归因于导致骨髓微脉管系统表达的P-和/或E-选择素的细胞表面分子的岩藻糖基化水平较低。这种相互作用是将造血祖细胞募集到骨髓中的关键组成部分。我们假设增加CB细胞表面构造水平将改善与选择素的相互作用,从而改善归巢和植入。 AIM 3将评估使用岩藻糖基转移酶的未操纵和扩展的CB祖细胞的修饰,以促进其募集到骨髓中。
公共卫生相关性:许多没有骨髓供体的高危血液恶性肿瘤和遗传疾病的患者越来越多地使用脐带血,与骨髓相比,植入术的时间更长。在输注之前,实验室中脐带血的扩张似乎缩短了植入的时间。另外,在输注之前,用糖分子对脐带血进行处理似乎可以提高其迅速回家的能力。这两种策略都将在赠款中探索,从而使患者在传染性和出血并发症方面更安全,从而提高生存率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
Elizabeth J Shpall其他文献
Efficacy and Safety of Gilteritinib Vs. Sorafenib As Post-Transplant Maintenance in Patients with FLT3-ITD Acute Myeloid Leukemia
- DOI:10.1182/blood-2022-16578010.1182/blood-2022-165780
- 发表时间:2022-11-152022-11-15
- 期刊:
- 影响因子:
- 作者:Jason Yeh;Rima M. Saliba;Christopher Wang;Zhou Fang;Bradley Figgins;Sairah Ahmed;Musa Yilmaz;Naval Daver;Rohtesh S. Mehta;Gheath Alatrash;David Marin;Uday R Popat;Richard E Champlin;Elizabeth J Shpall;Betul OranJason Yeh;Rima M. Saliba;Christopher Wang;Zhou Fang;Bradley Figgins;Sairah Ahmed;Musa Yilmaz;Naval Daver;Rohtesh S. Mehta;Gheath Alatrash;David Marin;Uday R Popat;Richard E Champlin;Elizabeth J Shpall;Betul Oran
- 通讯作者:Betul OranBetul Oran
Efficacy of Azacitidine Post-Transplant Maintenance for FLT3-Negative Acute Myeloid Leukemia and Myelodysplastic Syndrome
- DOI:10.1182/blood-2022-15933610.1182/blood-2022-159336
- 发表时间:2022-11-152022-11-15
- 期刊:
- 影响因子:
- 作者:Oren Pasvolsky;Rima M. Saliba;Uday R Popat;Amin M Alousi;Rohtesh S. Mehta;Jason Yeh;Gheath Alatrash;Adeel Masood;Jeremy L. Ramdial;Gabriela Rondon;Partow Kebriaei;Richard E Champlin;Elizabeth J Shpall;Betul OranOren Pasvolsky;Rima M. Saliba;Uday R Popat;Amin M Alousi;Rohtesh S. Mehta;Jason Yeh;Gheath Alatrash;Adeel Masood;Jeremy L. Ramdial;Gabriela Rondon;Partow Kebriaei;Richard E Champlin;Elizabeth J Shpall;Betul Oran
- 通讯作者:Betul OranBetul Oran
Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis
- DOI:10.1182/blood-2022-16638110.1182/blood-2022-166381
- 发表时间:2022-11-152022-11-15
- 期刊:
- 影响因子:
- 作者:Rohtesh S. Mehta;Rima M. Saliba;Amin M Alousi;Gheath Alatrash;Qaiser Bashir;Chitra Hosing;Partow Kebriaei;Issa F. Khouri;Yago Nieto;Betul Oran;Uday R Popat;Muzaffar H Qazilbash;Jeremy L. Ramdial;Gabriela Rondon;Samer A Srour;Katy Rezvani;Richard E Champlin;Elizabeth J Shpall;Kai CaoRohtesh S. Mehta;Rima M. Saliba;Amin M Alousi;Gheath Alatrash;Qaiser Bashir;Chitra Hosing;Partow Kebriaei;Issa F. Khouri;Yago Nieto;Betul Oran;Uday R Popat;Muzaffar H Qazilbash;Jeremy L. Ramdial;Gabriela Rondon;Samer A Srour;Katy Rezvani;Richard E Champlin;Elizabeth J Shpall;Kai Cao
- 通讯作者:Kai CaoKai Cao
Effect of Delayed Cell Infusion in Patients with Large B-Cell Lymphoma Treated with CAR T-Cell Therapy
- DOI:10.1182/blood-2022-16678310.1182/blood-2022-166783
- 发表时间:2022-11-152022-11-15
- 期刊:
- 影响因子:
- 作者:Andrew Jallouk;Lei Feng;Mansoor Noorani;Kaberi Das;Raphael E Steiner;Loretta J. Nastoupil;Misha Hawkins;Ranjit Nair;Jason Westin;Luis Fayad;Dai Chihara;Luis Enrique Malpica Castillo;Swaminathan P. Iyer;Sairah Ahmed;Elizabeth J Shpall;Partow Kebriaei;Sattva S. Neelapu;Paolo StratiAndrew Jallouk;Lei Feng;Mansoor Noorani;Kaberi Das;Raphael E Steiner;Loretta J. Nastoupil;Misha Hawkins;Ranjit Nair;Jason Westin;Luis Fayad;Dai Chihara;Luis Enrique Malpica Castillo;Swaminathan P. Iyer;Sairah Ahmed;Elizabeth J Shpall;Partow Kebriaei;Sattva S. Neelapu;Paolo Strati
- 通讯作者:Paolo StratiPaolo Strati
Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis
- DOI:10.1182/blood-2022-16647210.1182/blood-2022-166472
- 发表时间:2022-11-152022-11-15
- 期刊:
- 影响因子:
- 作者:Rohtesh S. Mehta;Rima M. Saliba;Amin M Alousi;Gheath Alatrash;Qaiser Bashir;Partow Kebriaei;Issa F. Khouri;Yago Nieto;Betul Oran;Uday R Popat;Muzaffar H Qazilbash;Jeremy L. Ramdial;Gabriela Rondon;Samer A Srour;Katy Rezvani;Richard E Champlin;Elizabeth J Shpall;Kai CaoRohtesh S. Mehta;Rima M. Saliba;Amin M Alousi;Gheath Alatrash;Qaiser Bashir;Partow Kebriaei;Issa F. Khouri;Yago Nieto;Betul Oran;Uday R Popat;Muzaffar H Qazilbash;Jeremy L. Ramdial;Gabriela Rondon;Samer A Srour;Katy Rezvani;Richard E Champlin;Elizabeth J Shpall;Kai Cao
- 通讯作者:Kai CaoKai Cao
共 15 条
- 1
- 2
- 3
Elizabeth J Shpall的其他基金
SPORE University of Texas M. D. Anderson Cancer Center-Leukemia
SPORE 德克萨斯大学 MD 安德森癌症中心 - 白血病
- 批准号:1091171310911713
- 财政年份:2023
- 资助金额:$ 31万$ 31万
- 项目类别:
Cord Blood Graft Engineering to Improve Engraftment and Reduce GVHD
脐带血移植工程可改善移植并减少 GVHD
- 批准号:1047815110478151
- 财政年份:2011
- 资助金额:$ 31万$ 31万
- 项目类别:
Cord Blood Expansion and Homing to Improve Engraftment
脐带血扩张和归巢以改善植入
- 批准号:93403089340308
- 财政年份:2011
- 资助金额:$ 31万$ 31万
- 项目类别:
Cord Blood Expansion and Homing to Improve Engraftment
脐带血扩张和归巢以改善植入
- 批准号:85553818555381
- 财政年份:2011
- 资助金额:$ 31万$ 31万
- 项目类别:
Cord Blood Graft Engineering to Improve Engraftment and Reduce GVHD
脐带血移植工程可改善移植并减少 GVHD
- 批准号:1024704110247041
- 财政年份:2011
- 资助金额:$ 31万$ 31万
- 项目类别:
Administrative, Regulatory and Cord Blood Bank
行政、监管和脐带血库
- 批准号:93403129340312
- 财政年份:2011
- 资助金额:$ 31万$ 31万
- 项目类别:
Administrative, Regulatory and Cord Blood Bank
行政、监管和脐带血库
- 批准号:85553858555385
- 财政年份:2011
- 资助金额:$ 31万$ 31万
- 项目类别:
Good Manufacturing Practice (GMP) and Immune Assessment Core
良好生产规范 (GMP) 和免疫评估核心
- 批准号:80001698000169
- 财政年份:2010
- 资助金额:$ 31万$ 31万
- 项目类别:
相似国自然基金
HO-1介导的铁死亡在噬血细胞综合征血小板减少及活化中的作用及其机制研究
- 批准号:82260028
- 批准年份:2022
- 资助金额:33.00 万元
- 项目类别:地区科学基金项目
HO-1介导的铁死亡在噬血细胞综合征血小板减少及活化中的作用及其机制研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
基于新型“CAR-血小板载药体系”的噬血细胞综合征免疫靶向治疗及机制研究
- 批准号:
- 批准年份:2021
- 资助金额:55 万元
- 项目类别:面上项目
基于新型“CAR-血小板载药体系”的噬血细胞综合征免疫靶向治疗及机制研究
- 批准号:82170224
- 批准年份:2021
- 资助金额:55.00 万元
- 项目类别:面上项目
基于造血微环境调节和造血细胞保护的血小板生成素抗辐射损伤作用机制研究
- 批准号:81202147
- 批准年份:2012
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome.
推进 BITT-101 成为一种新型 CD40 拮抗剂,用于治疗干燥综合征。
- 批准号:1076056810760568
- 财政年份:2023
- 资助金额:$ 31万$ 31万
- 项目类别:
Targeting HNF4-induced thrombo-inflammation in Chagas disease
针对恰加斯病中 HNF4 诱导的血栓炎症
- 批准号:1072726810727268
- 财政年份:2023
- 资助金额:$ 31万$ 31万
- 项目类别:
Synthetic circuits for therapeutic platelet production and immunomodulation
用于治疗性血小板生成和免疫调节的合成回路
- 批准号:1074523710745237
- 财政年份:2023
- 资助金额:$ 31万$ 31万
- 项目类别:
Roles of mRNA Transfer in Cancer Cell-Platelet Communication
mRNA 转移在癌细胞-血小板通讯中的作用
- 批准号:1074853510748535
- 财政年份:2023
- 资助金额:$ 31万$ 31万
- 项目类别:
Pathogenesis of thrombotic microangiopathies
血栓性微血管病的发病机制
- 批准号:1060874010608740
- 财政年份:2023
- 资助金额:$ 31万$ 31万
- 项目类别: